In the study, it was found that after DCXC treatment with 10, 30 and 60 mg/kg, inflammatory cell exudation and pulmonary edema were alleviated to a certain extent, and the levels of TNF-α, IL-6 and IL-1β in BALF were also reduced to a certain extent in a dose-dependent manner. The gene discussed is IL1B; the disease is edema.